Insights Terminal

AI-powered analytics platform delivering actionable market insights from insider transactions, enabling data-driven decisions for investors.

[Insights Terminal @InsTerminal]

We pay attention when a key executive takes significant chips off the table precisely as their company scales up its leverage to historical levels.

McBee Brannin, the Chief Development Officer of $CRWV, sold almost $12 million worth of shares last week.

CoreWeave's Q4 2025 earnings, reported in late February, showcased the dual reality of the AI infrastructure boom.

On the top line, the growth is staggering. The company hit $5.1 billion in revenue for the year, up 168% YoY, and expanded its contracted revenue backlog to a massive $66.8 billion.

However, the bottom line tells a different story.

CoreWeave posted a Q4 net loss of $452 million and missed EPS forecasts heavily, reporting an $0.89 loss per share against a projected $0.21 loss.

This profitability drag is directly tied to the aggressive pace at which CRWV is building out data centers and acquiring GPUs to meet its multi-year customer commitments.

The balance sheet is where the risk lies.

CoreWeave entered this year with debt levels approaching the $30 billion mark. To put the cost of that leverage into perspective, its Q4 interest expense alone was $388 million. Nearly triple the amount from the prior year.

Because Coreweave operates as an AI utility provider, it is utilizing massive leverage to fund long-life infrastructure assets.

While this is structurally normal for a capital-intensive business, the pure scale of the borrowing means a significant portion of its incoming revenue is being immediately diverted to service debt.

Over the past two weeks, two major developments occurred alongside the insider selling as well.

On March 31, CoreWeave officially closed an $8.5 billion delayed draw term loan facility. This investment-grade, GPU-backed financing is designed to give them staged access to capital to further expand their infrastructure.

On April 1, the company announced positive performance results from the MLPerf Inference benchmark suite, reinforcing its technical positioning in the data center space.

Our take on the context behind McBee's insider trade comes down to risk management during a highly leveraged growth phase.

While the trades were executed under a Rule 10b5-1 trading plan established back in November 2025, the timing aligns perfectly with CoreWeave's shifting capital structure.

The company has a guaranteed $66.8 billion backlog, but management projects 2026 capital expenditures to run between $30 billion and $35 billion.

[Insights Terminal @InsTerminal]

Reed Hastings just executed a major stock sale, and to understand why the market is digesting this smoothly, you have to look at what $NFLX recently walked away from.

In the last couple of weeks, the biggest Netflix news was its decision to walk away from the $82 billion acquisition of $WBD.

Instead of taking on massive integration risks and cultural complexities, Netflix secured a $2.8 billion termination fee.

At the same time, Netflix announced another round of US price hikes, pushing the Premium tier to $26.99, the Standard ad-free tier to $19.99, and the ad-supported tier to $8.99.

Adding the $2.8 billion termination fee to its existing cash reserves brings total liquidity to approximately $11.8 billion. Against a net debt position of just over $5 billion, the balance sheet is exceptionally clean for a media company of this scale.

This financial footing is supported by its recent Q4 earnings, where Netflix posted an EPS of $0.56 and revenue of $12.05 billion, representing a 17.6% YoY increase. The forward-looking fundamentals are highly supportive, particularly with advertising revenue on track to double to over $3 billion for 2026.

So what is the context behind Reed Hastings exercising options and selling 420,550 shares for roughly $40.1 million on April 1? Our take is that this is a non-event fundamentally. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established back in August 2023. While it was a sizable open-market transaction in the $95 to $97 range, Hastings still retains an indirect holding of over 21 million shares through his family trust.

Given the company's robust liquidity, clean debt profile, and a management team demonstrating strict M&A discipline, a founder executing a scheduled liquidity event is simply routine portfolio management.

[Insights Terminal @InsTerminal]

We find it highly revealing when a CEO steps in to buy seven figures of company stock on the open market just days after heavily reshaping the balance sheet with a massive debt and equity raise.

Looking at Zenas BioPharma $ZBIO, CEO Leon O. Moulder Jr. spent over $1.02 million across March 30 and March 31, 2026, acquiring 54,000 shares at average prices between $18.23 and $19.31.

To understand why he is stepping in now, we have to look at the immediate fundamental context of the business.

The company just reported its Q4 and full-year 2025 earnings in mid-March, and the cash burn is steep.

ZBIO posted a full-year net loss of $377.7 million against roughly $10 million in revenue. That loss was heavily inflated by $171.7 million in acquired in-process R&D expenses tied to a license agreement with InnoCare, alongside escalating R&D costs.

While they ended 2025 with $360.5 million in cash and investments and no traditional long-term debt (aside from a $78.6 million royalty obligation), there were emerging going-concern risks regarding their cash runway that needed to be addressed.

To fix the balance sheet, management moved aggressively. In late March, ZBIO completed a $300 million capital raise, split between a $100 million equity offering priced at $20 per share, and $200 million in 2.5% senior unsecured convertible notes due in 2032.

On top of this, ZBIO secured a debt facility with Pharmakon for up to $250 million, unlocking $75 million upfront.

Our take is that this capital restructuring is the exact catalyst for Moulder’s insider buying. Moulder, alongside a company director (Fairmount Funds Management) which also just purchased $3 million in stock at $20 per share on March 31, is signaling that the funding overhang is cleared. The balance sheet is now fortified to support their pipeline.

The timing aligns perfectly with major clinical execution targets as well.

ZBIO recently reported that obexelimab showed a 95% reduction in brain lesions in a Phase 2 multiple sclerosis trial. More importantly, they are on track to submit a biologics license application to the FDA in the second quarter of 2026 for IgG4-related disease based on positive Phase 3 INDIGO data.

By taking on this mix of convertible notes and structured debt, Zenas accepted leverage and future dilution, but the company bought itself a clear path to commercialization.

Moulder’s $1.02 million purchase immediately following the raise is a direct statement that the cash runway they just secured is worth the cost of the dilution.

[Insights Terminal @InsTerminal]

It is always worth paying attention when a founding family trims its stake right after a stellar earnings print.

We noticed the Walton Family Holdings Trust recently executed a massive series of open-market sales, unloading roughly 3.3 million shares of $WMT for ~$403 million between March 24 and March 25.

The context behind this insider trade lies in Walmart’s current operational momentum and its resulting valuation.

The company just delivered an exceptionally strong Q4 2026 earnings report in late February. WMT beat the consensus estimate with an EPS of $0.74 and drove quarterly revenue up 5.6% YoY to $190.66 billion.

The standout metric is Walmart's digital acceleration. Global e-commerce grew by 24% and now accounts for 23% of total net sales. Operating income outpaced top-line growth, rising 10.8%.

The balance sheet further supports a picture of stability rather than distress. Walmart’s total debt sits at $67.09 billion, with long-term debt at $40.36 billion. Walmart's debt-to-total equity ratio is currently tracking at a very manageable 64.4%. This is a healthy, optimized capital structure for a retailer of this size.

This strength has allowed the management to confidently raise the annual dividend to $0.99 per share and pursue new strategic revenue streams, such as the VIZIO content-to-commerce integrations announced on March 23.

So what does the Walton Trust's stock sale actually tell us? The stock was trading between $122.32 and $123.10 during these late-March transactions. Following a massive 44% gain over the past year, Walmart's P/E ratio has stretched to nearly 45x. The company is currently priced for perfection.

The Trust’s decision to take $403 million off the table seems more like a logical response to peak market pricing and less like a warning sign about the underlying business.

They are capitalizing on the liquidity provided by a flawless earnings beat and robust e-commerce growth, all while still maintaining direct ownership of over 513 million shares.

[Insights Terminal @InsTerminal]

We've been watching Silver Lake’s recent activity in $DELL, and the timing of their distribution is worth a closer look.

Since the start of March, entities tied to the private equity firm have offloaded roughly 1.35 million shares, a move valued at over $200 million.

This selling comes right as $DELL trades near $188 (up 82% in 12 months) and follows a massive Q4 FY2026 earnings report that most would consider a "buy" signal.

The numbers for the Infrastructure Solutions Group were impressive, with AI-optimized server revenue growing 342% YoYto $9 billion.

Dell now sits on a $43 billion AI server backlog across 4,000 customers, but we noticed an interesting divergence in the capital structure that likely explains the insider selling.

Total debt has crept up to $31.5 billion, a 28% increase from a year ago.

While that’s far from the $48 billion peak of years past, it shows the company is leveraging up to fund a massive inventory build and support aggressive capital returns. Dell just authorized a fresh $10 billion share repurchase program, for context.

The missing link here seems to be engineered liquidity.

Silver Lake is essentially using the tailwinds of the AI infrastructure cycle and the company’s own buyback window to trim its long-held stake.

While the fundamental growth in AI hardware is undeniable, the rising debt profile suggests Dell is pulling every lever to sustain this momentum while its largest backers take chips off the table.

We're keeping a close eye on the pace of these filings to see if Silver Lake plans to accelerate its exit before the AI server backlog begins to normalize.

Follow Dell insiders at Insights Terminal: https://t.co/N4w0p6dkMI

[Insights Terminal @InsTerminal]

$FI has been decimated recently (down 70% YTD).

But insiders are finally stepping in to call the bottom.

We just spotted 2 purchases totaling $1.6M+ this week.

The new CFO has been quick to join the party. This could be a major signal that bad news is priced in.
#stocks

[Insights Terminal @InsTerminal]

October was a very active month for insiders.

From $DELL's Michael Dell selling $1 billion worth of shares to $KMI's Richard Kinder buying 1M shares, there were large buys and sells.

Read our October insider transactions summary for free: https://t.co/VRnQf1BTEt
#stocks

[Insights Terminal @InsTerminal]

$KMI Chairman Richard Kinder just bought the dip in a big way.

Last week, he loaded up on 1M shares for $26M at $25.96/share.

This came 5 days after $KMI's Q3 earnings, which caused a ~4.5% after-hours drop.

This is the largest single insider buy at $KMI in the last 12 months.

[Insights Terminal @InsTerminal]

$KO Director Max Levchin purchased 24,192 shares on Oct. 23 for ~$1 million.

This came just before Sky News reported that Coca-Cola is in talks with $KKR to sell the Costa Coffee business.

$KKR reportedly backed out in August but is now back at the table. This signals they (and other bidders like Bain) see a classic PE turnaround play in Costa - buy a massive, distressed brand at a steep discount.

Interesting times.

[Insights Terminal @InsTerminal]

$DELL has been on a tear this year, rising 32%.

Insiders seem to be cashing in on these gains.

CEO Michael Dell sold $1 billion worth of shares last week, while Director William Green also sold shares worth $7 million.

The bull case for Dell seems promising too, anyways.

Dell is aggressively expanding into the AI infrastructure market through its PowerEdge server portfolio and PowerSwitch networking solutions.

According to Bloomberg, the big 4 tech companies alone are expected to incur more than $320 billion in CapEx this year, with the bulk going towards AI infrastructure spending. Dell is positioned well to benefit from this spending.

At its Analyst Day event earlier this month, Dell meaningfully raised its long-term revenue and earnings growth projections as well.

Keep an eye on what insiders are doing amid these expansion efforts: https://t.co/VcHu1Jv1ei

#stocks #investing

[Insights Terminal @InsTerminal]

$CRWV 10% owner Magnetar Financial has sold ~355,000 shares last week.

This comes after a 235% YTD gain for $CRWV.

The company is quite interesting, to say the least.

Countries are now treating GPU compute capacity as a strategic national asset, just like energy or telecommunications.

But building a national AI cloud isn't easy. It requires speed, flexibility, and deep specialization. This is where a company like CoreWeave comes in. They're emerging as a go-to partner for sovereign deals.

Here's why:

1. CoreWeave can stand up massive, state-of-the-art $NVDA GPU clusters faster than many bureaucratic hyperscalers. For a nation in the global AI race, time is a critical competitive advantage.

2. They aren't trying to sell a suite of 100 other cloud services. They do one thing: deliver high-performance compute for AI. This singular focus is exactly what complex, mission-critical sovereign projects demand.

3. The Sovereign AI trend is creating a massive new customer category outside of the traditional enterprise/startup mold. Players like CoreWeave, who can act as nimble, specialized infrastructure partners, are uniquely positioned to capture this multi-billion-dollar wave.

We are keeping a close eye on $CRWV insider transactions as the growth story unfolds.

Check all transactions for free here: https://t.co/eD44Qya5wk

[Insights Terminal @InsTerminal]

Elon Musk bought $500 million+ worth of Tesla stock in September.

It's one of the largest insider buys of the year.

He was not the only notable insider who went on a buying spree in September.

What does the smart money know? Our full September Insider Trading Report breaks it down:

https://t.co/Kl7AYq3Gmp
#stocks

[Insights Terminal @InsTerminal]

$OPEN stock is up ~25% in the past 5 trading sessions.

Just before this recent rally, Director Eric Wu purchased $3 million worth of shares on Sep. 11.

The buy comes just as $OPEN undergoes a massive leadership shakeup.
#InsiderTrading #stocks

[Insights Terminal @InsTerminal]

Massive insider selling at $CRWV as the IPO lock-up period expires.

A director offloaded nearly $300M in shares, with Morgan Stanley, JPMorgan, and Goldman Sachs arranging over $1B in block trades.

This comes just months after the company's public debut in March.

Is this a red flag? Let's dive into the data.

The lock-up expiry freed up 84% of CoreWeave's shares, allowing insiders and early investors to cash in on the post-IPO rally.

While large-scale selling like this can create short-term pressure on the stock, it's not uncommon after a lock-up period ends. But there's more to this story.

Despite the insider sales, CoreWeave's growth is explosive. The company has a $30.1 billion revenue backlog and reported Q2 2025 revenue of $1.21 billion, a whopping 207% increase year-over-year.

They are at the heart of the AI revolution, providing the critical infrastructure for AI models.

But this growth comes at a cost. CoreWeave is burning through cash, with over $11B in debt and soaring interest expenses, which hit nearly $270M in Q2. Capex for 2025 is projected to be between $20B and $23B. This high-leverage strategy is a high-risk, high-reward bet on the continued growth of AI.

Wall Street is divided on $CRWV. Analyst ratings are mixed, with price targets ranging from as low as $23 to a high of $200. The consensus rating is a "Hold," reflecting the uncertainty surrounding the company's future profitability and the competitive landscape.

CoreWave is a hyper-growth AI play with significant insider selling and a mountain of debt. We are keeping a close eye on future insider transactions.

Follow us for more deep dives into insider transactions and what they really mean.
#stocks #insiders

[Insights Terminal @InsTerminal]

Jonathan Sobel, Chairman of $HTH subsidiary Hilltop Securities bought 30,000 shares of Hilltop Holdings last week (~$1M).

The context around the purchase makes these transactions interesting.

The buy comes just days after $HTH announced a new dual listing on NYSE Texas (Aug 14). This move could significantly boost trading liquidity and investor visibility.

Hilltop's last reported Book Value Per Share (Q2 2025) was $40.38. With the stock trading around $32.50, Sobel bought shares at a Price-to-Book (P/B) ratio of ~0.8x. Buying a bank stock for 80 cents on the dollar is a classic value signal.

The Chairman is likely betting that the market has not yet priced in the benefits of the new listing and the company's solid book value.

Follow us @InsTerminal for more actionable analysis of insider transactions.
#stocks #investing

[Insights Terminal @InsTerminal]

Last week, $LLY had its biggest stock drop in over 20 years, plunging ~14% after news on its next-gen obesity pill.

While the market panicked, $LLY's CEO, Chief Scientific Officer, and board members did the opposite.

They bought the dip. Nearly $2.9M in shares were snapped up by top insiders.

The drop was triggered by interim Phase 3 data for orforglipron, $LLY's oral obesity drug.

While the drug showed effective weight loss, it came with a high rate of side effects (nausea, vomiting), leading to a ~17% discontinuation rate among trial participants.

This spooked investors who had priced $LLY for near-perfection.

This is where it gets interesting. The C-suite, who has the most intimate knowledge of the full drug pipeline and data, saw this as a buying opportunity.

SEC Filings from this week show:
1. CEO David Ricks: Bought $1.03M
2. Chief Scientific Officer Dan Skovronsky: Bought $634K
3. Board Members Sulzberger & Frywald: Bought over $1.1M combined

The market's reaction focused on one drug. But the insiders' confidence is likely rooted in the company's broader dominance.

Let's not forget the financial engines: Zepbound & Mounjaro.

Last quarter's revenue for these two drugs alone was over $6.5 Billion, showcasing one of the most successful drug launches in history. The orforglipron setback doesn't halt this massive growth engine.

For a complete picture, we also note that not every transaction was a buy.

Just before the trial data was released, Ilya Yuffa, President of Lilly USA, sold ~$784K worth of stock.

The bottom line: While Wall Street reacted to a short-term setback, Eli Lilly's core leadership sent a clear signal. They believe the 14% drop was an overreaction and that the company's long-term value is intact.

Want more data-driven insights on insider moves? Follow @InsightsTerminal.
#stocks #investing

[Insights Terminal @InsTerminal]

$HIMS CEO Andrew Dudum sold 660,000 shares of $HIMS on Aug 7, marking the largest insider sale in the company's history.

The transaction was valued at over $33 million.

This is a major insider transaction involving one of the most favorite stock among retail investors.
#InsiderTrading #stocks

[Insights Terminal @InsTerminal]

The U.S. Insider Buy/Sell Ratio is currently at a low 0.35.

This means that for every 1 share corporate insiders are buying, they are selling almost 3 shares.

Historically, major market bottoms (like 2008 & 2020) saw this ratio spike as insiders bought heavily when others panicked.

Today's low ratio suggests insiders aren't seeing deep value at current prices.

Not a sell signal on its own, but a key data point for staying cautious.
#insiders #stocks

[Insights Terminal @InsTerminal]

Insider selling spree at $PLTR is continuing in August.

Director Alexander Moore has sold ~20,000 shares so far this month at prices between $150 and $158.

Chief revenue officer Ryan Taylor also sold 30,000 shares at $175.
#insiders #stocks